Compare ZH & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZH | XOMA |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.6M | 457.6M |
| IPO Year | 2021 | N/A |
| Metric | ZH | XOMA |
|---|---|---|
| Price | $3.46 | $29.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.70 | ★ $69.50 |
| AVG Volume (30 Days) | ★ 222.4K | 58.2K |
| Earning Date | 11-25-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.17 | ★ 0.82 |
| Revenue | ★ $416,437,241.00 | $47,106,000.00 |
| Revenue This Year | N/A | $77.23 |
| Revenue Next Year | N/A | $17.97 |
| P/E Ratio | ★ $20.50 | $36.40 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $3.19 | $18.35 |
| 52 Week High | $6.32 | $39.92 |
| Indicator | ZH | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 26.56 | 37.26 |
| Support Level | $3.42 | $29.07 |
| Resistance Level | $4.14 | $31.44 |
| Average True Range (ATR) | 0.18 | 1.53 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 4.73 | 20.52 |
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.